Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02CUN
|
|||
| Former ID |
DIB010734
|
|||
| Drug Name |
NM504
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-10: E08-E13] | Phase 1 | [1] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 0 | [1], [2] | ||
| Company |
Microbiome therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01866462) Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.